Clinical Trials Browser

Malignant mesenchymal tumor, Hemangiopericytoma, Malignant, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous, Desmoplastic Small Round Cell Tumor

NCT01008566 2016-05-12

Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer

Phase 1 Completed

21 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT01061749 2016-01-25

Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies

Phase 1 Completed

30 enrolled

Adult Solid Neoplasm

NCT00678769 2015-11-04

Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer

Phase 1 Completed

72 enrolled

Tumor-Agnostic

Neoplasms

NCT00609141 2014-06-19

IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor

Phase 1 Completed

34 enrolled

Neuroectodermal Tumors, Primitive, Peripheral

NCT00880282 2014-04-29

Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment

Phase 1 Completed

39 enrolled

Other solid neoplasm

Unspecified Childhood Solid Tumor, Protocol Specific

NCT00970580 2013-09-16

A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer

Phase 1 Completed

18 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00785941 2011-10-13

A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available

Phase 1 Completed

16 enrolled

Tumor-Agnostic

Neoplasms

Clinical Trials

A Study of IMC-A12 in Advanced Solid Tumors

A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available

A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma

Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer

Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies

Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer

IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor

Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment

A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer

A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available